SecBot SecBot
144 ·Filed Jun 30, 2026

RAPP

Rapport Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago SEC0001950047-26-006648
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for subsequent Form 4 filing to confirm actual sale execution. The small size of this proposed sale suggests no material insider concern, but the pattern of recent insider selling (6 sales totaling $743K in 30 days) warrants watching for any acceleration.

DirectionNeutral
Confidencemedium
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
RAPP ▼ -14.12% at T+60d
NEUTRAL call ✗ call lost -14.12% · α vs SPY -17.07% · entry $39.39 → $33.83
Entry anchored
Jun 30, 03:59 PM ET
via exchange tick
T+1d
-1.07%
call -1.07% · α -0.93%
$38.97
settled 4mo ago
T+5d
+0.84%
call +0.84% · α +0.58%
$39.72
settled 4mo ago
T+20d
+3.94%
call +3.94% · α +6.12%
$40.94
settled 3mo ago
T+60d
-14.12%
call -14.12% · α -17.07%
$33.83
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Cheryl Gault, an officer of Rapport Therapeutics, filed a Form 144 on June 30, 2026, indicating intent to sell 10,000 shares of common stock, valued at approximately $403,900. The shares were acquired as founders' shares in September 2024. The proposed sale is small relative to the company's $1.9B market cap and represents a routine insider filing with minimal immediate market impact.

Key Facts

  • Insider: Cheryl Gault (officer) filed Form 144 on 2026-06-30
  • Proposed sale: 10,000 shares of common stock
  • Estimated value: ~$403,900 based on filing date
  • Shares acquired as founders' shares on 09/05/2024
  • Broker: Morgan Stanley Smith Barney LLC

Financial Impact

Proposed sale of ~$403,900, representing approximately 0.02% of shares outstanding — immaterial to company valuation

dilution

Risk Factors

  • Insider selling could signal reduced confidence, though the amount here is negligible
  • Form 144 is only an intent to sell; the sale may not occur

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006648
Document: 0001950047-26-006648-index.html0001950047-26-006648
Document: 0001950047-26-006648.txt0001950047-26-006648
22 reports for RAPP
Performance horizon
67% Hit rate @ T+5 4 of 6 directional calls Went positive at some point 6 of 8 best @ T+60▲ +24.87%Mar 10, 2026
Filters
Rows
Reports for RAPP — sortable, filterable
TypeNow
Oct 23, 2026
2d ago
Insider Cluster
BULLISH ★ 5/10
$26.00awaiting T+5—$25.93 (−0.27%)
Oct 22, 2026
4d ago
Insider Cluster
BULLISH ★ 5/10
$27.33awaiting T+5—$25.93 (−5.12%)
Oct 21, 2026
4d ago
Insider Buy
BULLISH ★ 4/10
$26.53awaiting T+5—$25.93 (−2.26%)
Oct 20, 2026
6d ago
8-K
BULLISH ★ 7/10
$29.37awaiting T+5—$25.93 (−11.71%)
Oct 6, 2026
19d ago
144
BEARISH ★ 5/10
$30.86 $28.33▲ +8.20%▲ +7.22%$25.93 (+15.98%)
Oct 1, 2026
24d ago
Insider Cluster
NEUTRAL ★ 3/10
$32.17 $30.65▼ −4.72%▼ −5.89%$25.93 (−19.40%)
Aug 26, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$50.83 $47.65▼ −6.26%▼ −6.52%$25.93 (−48.99%)
Aug 5, 2026
11w ago
8-K
MIXED ★ 5/10
$42.44 $47.73▲ +12.46%▲ +12.11%$25.93 (−38.90%)
Jul 1, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$38.97 $41.75▲ +7.13%▲ +5.77%$25.93 (−33.46%)
Jun 30, 2026
16w ago
144
NEUTRAL ★ 2/10
$39.39 $39.72▲ +0.84%▲ +0.58%$25.93 (−34.17%)
Showing 10 of 22

US Market Status

Market Closed — Opens in 2h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers